Technology Bundle ID: TAB-2621

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Request More Info
Licensing Contact:
Primary Inventors: 
Vera Semenova (CDC)
Co-Inventors: 
Conrad Quinn (CDC), Jan Pohl (CDC), Jarad Schiffer (CDC), Pavel Svoboda (CDC), Shannon Dalton (CDC), Stephen Soroka (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Pre-clinical
  • In vitro data available
Institute or Center: 
CDC

Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.

Applications:
  • Novel anthrax vaccines
  • Post-vaccination screening to determine if anthrax protection is achieved
  • Biodefense
Advantages:
  • May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
  • Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.

Patents

PCT Application PCT/US2011/024317
Filed on 2011-02-10
PCT Application PCT/US2014/052895
Filed on 2014-08-27
US Pat 9,046,520

Issued 2015-06-02
US Pat 9,102,742

Issued 2015-08-11
US Pat 9,610,338

Issued 2017-04-04
US Pat 9,782,465

Issued 2017-10-10

Updated

Aug 23, 2013

Data Source: 
tts